{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:03:04Z","timestamp":1784217784695,"version":"3.55.0"},"reference-count":217,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Passive immunotherapy targeting amyloid-\u03b2 (A\u03b2) has emerged as a major therapeutic strategy for Alzheimer\u2019s disease (AD), yet its clinical benefits remain modest and are frequently accompanied by vascular adverse events such as amyloid-related imaging abnormalities (ARIA). While the removal of extracellular A\u03b2 plaques is associated with therapeutic efficacy, accumulating evidence suggests that additional cellular and vascular mechanisms may also contribute to complementary therapeutic outcomes alongside plaque removal. Recent studies show that A\u03b2 antibodies are broadly distributed within the brain and interact with multiple neural and immune cell populations, rather than being limited to A\u03b2 plaques. These observations support an expanded view of passive A\u03b2 immunotherapy as a multicellular coordinated clearance process. A\u03b2 antibodies engage diverse cellular and anatomical compartments, including neurons, glial cells, perivascular macrophages, peripheral immune cells, and meningeal lymphatic pathways, thereby influencing A\u03b2 dynamics across intracellular and extracellular pools. Within this framework, therapeutic outcomes are influenced not only by plaque clearance but also by interactions between A\u03b2 antibodies and cellular and anatomical compartments that regulate A\u03b2 clearance and treatment-associated vascular response. This perspective may help explain variability in clinical efficacy and the emergence of vascular side effects, while also providing additional considerations for optimizing A\u03b2 antibody design and therapeutic strategies.<\/jats:p>","DOI":"10.1186\/s13024-026-00972-y","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:27:37Z","timestamp":1784179657000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Passive amyloid-\u03b2 immunotherapy in Alzheimer\u2019s disease: a multicellular clearance system beyond plaque removal"],"prefix":"10.1186","volume":"21","author":[{"given":"Xiaoni","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Lindblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Deierborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asgeir","family":"Kobro-Flatmoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar K.","family":"Gouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-2167","authenticated-orcid":false,"given":"Gehua","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"972_CR1","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/ijbs.57078","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wei W, Zhao M, Ma L, Jiang X, Pei H, Cao Y, Li H. Interaction between Abeta and Tau in the Pathogenesis of Alzheimer\u2019s Disease. Int J Biol Sci. 2021;17:2181\u201392.","journal-title":"Int J Biol Sci"},{"key":"972_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.expneurol.2009.07.035","volume":"223","author":"TE Golde","year":"2010","unstructured":"Golde TE, Petrucelli L, Lewis J. Targeting Abeta and tau in Alzheimer\u2019s disease, an early interim report. Exp Neurol. 2010;223:252\u201366.","journal-title":"Exp Neurol"},{"key":"972_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","volume":"19","author":"EE Congdon","year":"2023","unstructured":"Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol. 2023;19:715\u201336.","journal-title":"Nat Rev Neurol"},{"key":"972_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"EE Congdon","year":"2018","unstructured":"Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018;14:399\u2013415.","journal-title":"Nat Rev Neurol"},{"key":"972_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41582-025-01123-5","volume":"21","author":"MS Rafii","year":"2025","unstructured":"Rafii MS, Aisen PS. Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions. Nat Rev Neurol. 2025;21:490\u20138.","journal-title":"Nat Rev Neurol"},{"key":"972_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"972_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136.","journal-title":"Nature"},{"key":"972_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"972_CR9","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/alz.12379","volume":"17","author":"E Richard","year":"2021","unstructured":"Richard E, den Brok M, van Gool WA. Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer\u2019s disease. Alzheimers Dement. 2021;17:1051\u20135.","journal-title":"Alzheimers Dement"},{"key":"972_CR10","doi-asserted-by":"publisher","first-page":"n156","DOI":"10.1136\/bmj.n156","volume":"372","author":"SF Ackley","year":"2021","unstructured":"Ackley SF, Zimmerman SC, Brenowitz WD, Tchetgen Tchetgen EJ, Gold AL, Manly JJ, Mayeda ER, Filshtein TJ, Power MC, Elahi FM, et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ. 2021;372:n156.","journal-title":"BMJ"},{"key":"972_CR11","doi-asserted-by":"publisher","first-page":"e71121","DOI":"10.1002\/alz.71121","volume":"22","author":"G Wen","year":"2026","unstructured":"Wen G, Lindblom N, Zhan X, Garcia-Ryde M, Deierborg T, Kobro-Flatmoen A, Gouras GK. Abeta antibodies target not only amyloid plaques but also distinct brain cells and vessels. Alzheimers Dement. 2026;22:e71121.","journal-title":"Alzheimers Dement"},{"key":"972_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00401-010-0679-9","volume":"119","author":"GK Gouras","year":"2010","unstructured":"Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer\u2019s disease. Acta Neuropathol. 2010;119:523\u201341.","journal-title":"Acta Neuropathol"},{"key":"972_CR13","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1016\/j.tjpad.2024.100013","volume":"12","author":"Z Valiukas","year":"2025","unstructured":"Valiukas Z, Tangalakis K, Apostolopoulos V, Feehan J. Microglial activation states and their implications for Alzheimer\u2019s Disease. J Prev Alzheimers Dis. 2025;12:100013.","journal-title":"J Prev Alzheimers Dis"},{"key":"972_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.molmed.2017.03.008","volume":"23","author":"FL Yeh","year":"2017","unstructured":"Yeh FL, Hansen DV, Sheng M. TREM2, Microglia, and Neurodegenerative Diseases. Trends Mol Med. 2017;23:512\u201333.","journal-title":"Trends Mol Med"},{"key":"972_CR15","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41591-025-03574-1","volume":"31","author":"L van Olst","year":"2025","unstructured":"van Olst L, Simonton B, Edwards AJ, Forsyth AV, Boles J, Jamshidi P, Watson T, Shepard N, Krainc T, Argue BM, et al. Microglial mechanisms drive amyloid-beta clearance in immunized patients with Alzheimer\u2019s disease. Nat Med. 2025;31:1604\u201316.","journal-title":"Nat Med"},{"key":"972_CR16","doi-asserted-by":"crossref","unstructured":"Cadiz MP, Gibson KA, Todd KT, Nascari DG, Massa N, Lilley MT, Olney KC, Al-Amin MM, Jiang H, Holtzman DM, Fryer JD. Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. J Exp Med. 2024;221(2):e20231363.","DOI":"10.1084\/jem.20231363"},{"key":"972_CR17","doi-asserted-by":"publisher","first-page":"7873","DOI":"10.1523\/JNEUROSCI.22-18-07873.2002","volume":"22","author":"BJ Bacskai","year":"2002","unstructured":"Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci. 2002;22:7873\u20138.","journal-title":"J Neurosci"},{"key":"972_CR18","doi-asserted-by":"publisher","first-page":"8532","DOI":"10.1523\/JNEUROSCI.23-24-08532.2003","volume":"23","author":"P Das","year":"2003","unstructured":"Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-\/- knock-out mice. J Neurosci. 2003;23:8532\u20138.","journal-title":"J Neurosci"},{"key":"972_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12974-018-1134-4","volume":"15","author":"S Sollvander","year":"2018","unstructured":"Sollvander S, Nikitidou E, Gallasch L, Zysk M, Soderberg L, Sehlin D, Lannfelt L, Erlandsson A. The Abeta protofibril selective antibody mAb158 prevents accumulation of Abeta in astrocytes and rescues neurons from Abeta-induced cell death. J Neuroinflammation. 2018;15:98.","journal-title":"J Neuroinflammation"},{"key":"972_CR20","doi-asserted-by":"publisher","first-page":"e00540","DOI":"10.1016\/j.neurot.2025.e00540","volume":"22","author":"R Ziar","year":"2025","unstructured":"Ziar R, Tesar PJ, Clayton BLL. Astrocyte and oligodendrocyte pathology in Alzheimer\u2019s disease. Neurotherapeutics. 2025;22:e00540.","journal-title":"Neurotherapeutics"},{"key":"972_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13024-023-00649-w","volume":"18","author":"X Taylor","year":"2023","unstructured":"Taylor X, Clark IM, Fitzgerald GJ, Oluoch H, Hole JT, DeMattos RB, Wang Y, Pan F. Amyloid-beta (Abeta) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer\u2019s disease mice. Mol Neurodegener. 2023;18:59.","journal-title":"Mol Neurodegener"},{"key":"972_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-024-00758-0","volume":"19","author":"X Taylor","year":"2024","unstructured":"Taylor X, Noristani HN, Fitzgerald GJ, Oluoch H, Babb N, McGathey T, Carter L, Hole JT, Lacor PN, DeMattos RB, Wang Y. Amyloid-beta (Abeta) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer\u2019s disease. Mol Neurodegener. 2024;19:77.","journal-title":"Mol Neurodegener"},{"key":"972_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41586-021-03489-0","volume":"593","author":"S Da Mesquita","year":"2021","unstructured":"Da Mesquita S, Papadopoulos Z, Dykstra T, Brase L, Farias FG, Wall M, Jiang H, Kodira CD, de Lima KA, Herz J, et al. Meningeal lymphatics affect microglia responses and anti-Abeta immunotherapy. Nature. 2021;593:255\u201360.","journal-title":"Nature"},{"key":"972_CR24","doi-asserted-by":"publisher","first-page":"534","DOI":"10.14283\/jpad.2021.52","volume":"8","author":"MB Usman","year":"2021","unstructured":"Usman MB, Bhardwaj S, Roychoudhury S, Kumar D, Alexiou A, Kumar P, Ambasta RK, Prasher P, Shukla S, Upadhye V, et al. Immunotherapy for Alzheimer\u2019s Disease: Current Scenario and Future Perspectives. J Prev Alzheimers Dis. 2021;8:534\u201351.","journal-title":"J Prev Alzheimers Dis"},{"key":"972_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","volume":"11","author":"C Song","year":"2022","unstructured":"Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L, Zhang R, Wang H, Chen H. Immunotherapy for Alzheimer\u2019s disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022;11:18.","journal-title":"Transl Neurodegener"},{"key":"972_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1073\/pnas.93.1.452","volume":"93","author":"B Solomon","year":"1996","unstructured":"Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A. 1996;93:452\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"972_CR27","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1073\/pnas.94.8.4109","volume":"94","author":"B Solomon","year":"1997","unstructured":"Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A. 1997;94:4109\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"972_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173\u20137.","journal-title":"Nature"},{"key":"972_CR29","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/35050116","volume":"408","author":"D Morgan","year":"2000","unstructured":"Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease. Nature. 2000;408:982\u20135.","journal-title":"Nature"},{"key":"972_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","volume":"64","author":"AJ Bayer","year":"2005","unstructured":"Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. 2005;64:94\u2013101.","journal-title":"Neurology"},{"key":"972_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46\u201354.","journal-title":"Neurology"},{"key":"972_CR32","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","volume":"65","author":"JA Nicoll","year":"2006","unstructured":"Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006;65:1040\u20138.","journal-title":"J Neuropathol Exp Neurol"},{"key":"972_CR33","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1749-6632.2000.tb06943.x","volume":"920","author":"CA Lemere","year":"2000","unstructured":"Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Desai R, Hancock WW, Weiner HL, Selkoe DJ. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann N Y Acad Sci. 2000;920:328\u201331.","journal-title":"Ann N Y Acad Sci"},{"key":"972_CR34","doi-asserted-by":"publisher","first-page":"104665","DOI":"10.1016\/j.ebiom.2023.104665","volume":"94","author":"HJ Yu","year":"2023","unstructured":"Yu HJ, Dickson SP, Wang PN, Chiu MJ, Huang CC, Chang CC, Liu H, Hendrix SB, Dodart JC, Verma A, et al. Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 2a study. EBioMedicine. 2023;94:104665.","journal-title":"EBioMedicine"},{"key":"972_CR35","doi-asserted-by":"publisher","first-page":"e70776","DOI":"10.1002\/alz.70776","volume":"21","author":"M Pascual-Lucas","year":"2025","unstructured":"Pascual-Lucas M, Lacosta AM, Montanes M, Canudas J, Loscos J, Monleon I, Allue JA, Sarasa L, Fandos N, Romero J, et al. Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Abeta40 in patients with mild cognitive impairment or very mild Alzheimer\u2019s disease: A randomized, double-blind, placebo-controlled phase 2 study. Alzheimers Dement. 2025;21:e70776.","journal-title":"Alzheimers Dement"},{"key":"972_CR36","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916\u20139.","journal-title":"Nat Med"},{"key":"972_CR37","doi-asserted-by":"publisher","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"RB DeMattos","year":"2001","unstructured":"DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2001;98:8850\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"972_CR38","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1523\/JNEUROSCI.2021-09.2009","volume":"29","author":"K Yamada","year":"2009","unstructured":"Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Ohtsuki S, Terasaki T, Hashimoto T, Iwatsubo T. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci. 2009;29:11393\u20138.","journal-title":"J Neurosci"},{"key":"972_CR39","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1126\/science.1078259","volume":"298","author":"M Pfeifer","year":"2002","unstructured":"Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002;298:1379.","journal-title":"Science"},{"key":"972_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nbd.2003.09.015","volume":"15","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis. 2004;15:11\u201320.","journal-title":"Neurobiol Dis"},{"key":"972_CR41","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1523\/JNEUROSCI.4337-04.2005","volume":"25","author":"MM Racke","year":"2005","unstructured":"Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci. 2005;25:629\u201336.","journal-title":"J Neurosci"},{"key":"972_CR42","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:322\u201333.","journal-title":"N Engl J Med"},{"key":"972_CR43","doi-asserted-by":"publisher","first-page":"105010","DOI":"10.1016\/j.nbd.2020.105010","volume":"144","author":"SS Plotkin","year":"2020","unstructured":"Plotkin SS, Cashman NR. Passive immunotherapies targeting Abeta and tau in Alzheimer\u2019s disease. Neurobiol Dis. 2020;144:105010.","journal-title":"Neurobiol Dis"},{"key":"972_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1586\/eci.11.93","volume":"8","author":"BP Imbimbo","year":"2012","unstructured":"Imbimbo BP, Ottonello S, Frisardi V, Solfrizzi V, Greco A, Seripa D, Pilotto A, Panza F. Solanezumab for the treatment of mild-to-moderate Alzheimer\u2019s disease. Expert Rev Clin Immunol. 2012;8:135\u201349.","journal-title":"Expert Rev Clin Immunol"},{"key":"972_CR45","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3233\/ADR-230025","volume":"7","author":"DA Loeffler","year":"2023","unstructured":"Loeffler DA. Antibody-Mediated Clearance of Brain Amyloid-beta: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Abeta Antibodies, and Downstream Effects. J Alzheimers Dis Rep. 2023;7:873\u201399.","journal-title":"J Alzheimers Dis Rep"},{"key":"972_CR46","doi-asserted-by":"publisher","first-page":"18325","DOI":"10.1074\/jbc.M117.801514","volume":"292","author":"J Zhao","year":"2017","unstructured":"Zhao J, Nussinov R, Ma B. Mechanisms of recognition of amyloid-beta (Abeta) monomer, oligomer, and fibril by homologous antibodies. J Biol Chem. 2017;292:18325\u201343.","journal-title":"J Biol Chem"},{"key":"972_CR47","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:311\u201321.","journal-title":"N Engl J Med"},{"key":"972_CR48","first-page":"1359","volume":"7","author":"D Novakovic","year":"2013","unstructured":"Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi C, Errico F, Mercuri NB, Nicoletti F, Nistico R. Profile of gantenerumab and its potential in the treatment of Alzheimer\u2019s disease. Drug Des Devel Ther. 2013;7:1359\u201364.","journal-title":"Drug Des Devel Ther"},{"key":"972_CR49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis. 2012;28:49\u201369.","journal-title":"J Alzheimers Dis"},{"key":"972_CR50","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","volume":"69","author":"S Ostrowitzki","year":"2012","unstructured":"Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69:198\u2013207.","journal-title":"Arch Neurol"},{"key":"972_CR51","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2174\/156720512803569064","volume":"9","author":"GB Freeman","year":"2012","unstructured":"Freeman GB, Brown TP, Wallace K, Bales KR. Chronic administration of an aglycosylated murine antibody of ponezumab does not worsen microhemorrhages in aged Tg2576 mice. Curr Alzheimer Res. 2012;9:1059\u201368.","journal-title":"Curr Alzheimer Res"},{"key":"972_CR52","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jmb.2011.11.047","volume":"421","author":"SL La Porte","year":"2012","unstructured":"La Porte SL, Bollini SS, Lanz TA, Abdiche YN, Rusnak AS, Ho WH, Kobayashi D, Harrabi O, Pappas D, Mina EW, et al. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer\u2019s disease. J Mol Biol. 2012;421:525\u201336.","journal-title":"J Mol Biol"},{"key":"972_CR53","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.trci.2017.05.003","volume":"3","author":"JW Landen","year":"2017","unstructured":"Landen JW, Andreasen N, Cronenberger CL, Schwartz PF, Borjesson-Hanson A, Ostlund H, Sattler CA, Binneman B, Bednar MM. Ponezumab in mild-to-moderate Alzheimer\u2019s disease: Randomized phase II PET-PIB study. Alzheimers Dement (N Y). 2017;3:393\u2013401.","journal-title":"Alzheimers Dement (N Y)"},{"key":"972_CR54","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/WNF.0b013e31827db49b","volume":"36","author":"JW Landen","year":"2013","unstructured":"Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing CB Jr., Bales K, Alvey C, McCush F, Yang J, et al. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin Neuropharmacol. 2013;36:14\u201323.","journal-title":"Clin Neuropharmacol"},{"key":"972_CR55","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S. Aducanumab: First Approval. Drugs. 2021;81:1437\u201343.","journal-title":"Drugs"},{"key":"972_CR56","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/psyg.12944","volume":"23","author":"A Rahman","year":"2023","unstructured":"Rahman A, Hossen MA, Chowdhury MFI, Bari S, Tamanna N, Sultana SS, Haque SN, Al Masud A, Saif-Ur-Rahman KM. Aducanumab for the treatment of Alzheimer\u2019s disease: a systematic review. Psychogeriatrics. 2023;23:512\u201322.","journal-title":"Psychogeriatrics"},{"key":"972_CR57","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","volume":"8","author":"JW Arndt","year":"2018","unstructured":"Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, Walz T, Pepinsky RB, Bussiere T, Hamann S, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta. Sci Rep. 2018;8:6412.","journal-title":"Sci Rep"},{"key":"972_CR58","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3233\/JAD-215065","volume":"83","author":"S Mukhopadhyay","year":"2021","unstructured":"Mukhopadhyay S, Banerjee D. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer\u2019s Disease. J Alzheimers Dis. 2021;83:1537\u201352.","journal-title":"J Alzheimers Dis"},{"key":"972_CR59","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3233\/JAD-200715","volume":"79","author":"J Bastrup","year":"2021","unstructured":"Bastrup J, Hansen KH, Poulsen TBG, Kastaniegaard K, Asuni AA, Christensen S, Belling D, Helboe L, Stensballe A, Volbracht C. Anti-Abeta Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer\u2019s Disease. J Alzheimers Dis. 2021;79:249\u201365.","journal-title":"J Alzheimers Dis"},{"key":"972_CR60","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease. J Prev Alzheimers Dis. 2022;9:197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"key":"972_CR61","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamaneurol.2021.3126","volume":"78","author":"V Planche","year":"2021","unstructured":"Planche V, Villain N. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials? JAMA Neurol. 2021;78:1307\u20138.","journal-title":"JAMA Neurol"},{"key":"972_CR62","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00259-023-06177-5","volume":"50","author":"A Verger","year":"2023","unstructured":"Verger A, Yakushev I, Albert NL, van Berckel B, Brendel M, Cecchin D, Fernandez PA, Fraioli F, Guedj E, Morbelli S, et al. FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective. Eur J Nucl Med Mol Imaging. 2023;50:1553\u20135.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"972_CR63","doi-asserted-by":"crossref","unstructured":"Lannfelt L. A light at the end of the tunnel\u2014from mutation identification to a potential treatment for Alzheimer\u2019s disease. Ups J Med Sci. 2023;128(1).","DOI":"10.48101\/ujms.v128.10316"},{"key":"972_CR64","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L Soderberg","year":"2023","unstructured":"Soderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, Moller C, Lannfelt L. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer\u2019s Disease. Neurotherapeutics. 2023;20:195\u2013206.","journal-title":"Neurotherapeutics"},{"key":"972_CR65","doi-asserted-by":"publisher","first-page":"14411","DOI":"10.1523\/JNEUROSCI.3537-10.2010","volume":"30","author":"B O\u2019Nuallain","year":"2010","unstructured":"O\u2019Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, Collinge J, Walsh DM. Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci. 2010;30:14411\u20139.","journal-title":"J Neurosci"},{"key":"972_CR66","doi-asserted-by":"publisher","first-page":"e32014","DOI":"10.1371\/journal.pone.0032014","volume":"7","author":"D Sehlin","year":"2012","unstructured":"Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, Lannfelt L, Pettersson FE. Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation. PLoS ONE. 2012;7:e32014.","journal-title":"PLoS ONE"},{"key":"972_CR67","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/alzrt272","volume":"6","author":"WF Goure","year":"2014","unstructured":"Goure WF, Krafft GA, Jerecic J, Hefti F. Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer\u2019s disease immunotherapeutics. Alzheimers Res Ther. 2014;6:42.","journal-title":"Alzheimers Res Ther"},{"key":"972_CR68","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1021\/bi500957g","volume":"54","author":"MR Nichols","year":"2015","unstructured":"Nichols MR, Colvin BA, Hood EA, Paranjape GS, Osborn DC, Terrill-Usery SE. Biophysical comparison of soluble amyloid-beta(1\u201342) protofibrils, oligomers, and protofilaments. Biochemistry. 2015;54:2193\u2013204.","journal-title":"Biochemistry"},{"key":"972_CR69","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid beta-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther. 2023;8:248.","journal-title":"Signal Transduct Target Ther"},{"key":"972_CR70","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/jnc.15030","volume":"155","author":"IC Fontana","year":"2020","unstructured":"Fontana IC, Zimmer AR, Rocha AS, Gosmann G, Souza DO, Lourenco MV, Ferreira ST, Zimmer ER. Amyloid-beta oligomers in cellular models of Alzheimer\u2019s disease. J Neurochem. 2020;155:348\u201369.","journal-title":"J Neurochem"},{"key":"972_CR71","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","volume":"129","author":"KL Viola","year":"2015","unstructured":"Viola KL, Klein WL. Amyloid beta oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129:183\u2013206.","journal-title":"Acta Neuropathol"},{"key":"972_CR72","doi-asserted-by":"publisher","first-page":"124231","DOI":"10.1016\/j.ijbiomac.2023.124231","volume":"239","author":"S Ghosh","year":"2023","unstructured":"Ghosh S, Ali R, Verma S. Abeta-oligomers: A potential therapeutic target for Alzheimer\u2019s disease. Int J Biol Macromol. 2023;239:124231.","journal-title":"Int J Biol Macromol"},{"key":"972_CR73","doi-asserted-by":"publisher","first-page":"103949","DOI":"10.1016\/j.mcn.2024.103949","volume":"130","author":"M Johannesson","year":"2024","unstructured":"Johannesson M, Soderberg L, Zachrisson O, Fritz N, Kylefjord H, Gkanatsiou E, Button E, Svensson AS, Rachalski A, Nygren P, et al. Lecanemab demonstrates highly selective binding to Abeta protofibrils isolated from Alzheimer\u2019s disease brains. Mol Cell Neurosci. 2024;130:103949.","journal-title":"Mol Cell Neurosci"},{"key":"972_CR74","doi-asserted-by":"publisher","first-page":"e2309389120","DOI":"10.1073\/pnas.2309389120","volume":"120","author":"ZL Chen","year":"2023","unstructured":"Chen ZL, Singh PK, Calvano M, Norris EH, Strickland S. A possible mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2023;120:e2309389120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"972_CR75","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","volume":"8","author":"V Logovinsky","year":"2016","unstructured":"Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, Basun H, Lannfelt L. Safety and tolerability of BAN2401\u2013a clinical study in Alzheimer\u2019s disease with a protofibril selective Abeta antibody. Alzheimers Res Ther. 2016;8:14.","journal-title":"Alzheimers Res Ther"},{"key":"972_CR76","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther. 2021;13:80.","journal-title":"Alzheimers Res Ther"},{"key":"972_CR77","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/d41573-024-00116-1","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. FDA approves third anti-amyloid antibody for Alzheimer disease. Nat Rev Drug Discov. 2024;23:571.","journal-title":"Nat Rev Drug Discov"},{"key":"972_CR78","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB Demattos","year":"2012","unstructured":"Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, et al. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer\u2019s disease mice. Neuron. 2012;76:908\u201320.","journal-title":"Neuron"},{"key":"972_CR79","doi-asserted-by":"publisher","first-page":"e12112","DOI":"10.1002\/trc2.12112","volume":"7","author":"SL Lowe","year":"2021","unstructured":"Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, Shcherbinin S, Ardayfio P, Sims JR. Donanemab (LY3002813) dose-escalation study in Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2021;7:e12112.","journal-title":"Alzheimers Dement (N Y)"},{"key":"972_CR80","doi-asserted-by":"publisher","first-page":"414","DOI":"10.14283\/jpad.2021.56","volume":"8","author":"SL Lowe","year":"2021","unstructured":"Lowe SL, Duggan Evans C, Shcherbinin S, Cheng YJ, Willis BA, Gueorguieva I, Lo AC, Fleisher AS, Dage JL, Ardayfio P, et al. Donanemab (LY3002813) Phase 1b Study in Alzheimer\u2019s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. J Prev Alzheimers Dis. 2021;8:414\u201324.","journal-title":"J Prev Alzheimers Dis"},{"key":"972_CR81","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, et al. Donanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med"},{"key":"972_CR82","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","volume":"82","author":"JA Zimmer","year":"2025","unstructured":"Zimmer JA, Ardayfio P, Wang H, Khanna R, Evans CD, Lu M, Sparks J, Andersen S, Lauzon S, Nery ESM, et al. Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials. JAMA Neurol. 2025;82:461\u20139.","journal-title":"JAMA Neurol"},{"key":"972_CR83","doi-asserted-by":"publisher","first-page":"e70062","DOI":"10.1002\/alz.70062","volume":"21","author":"H Wang","year":"2025","unstructured":"Wang H, Serap Monkul Nery E, Ardayfio P, Khanna R, Otero Svaldi D, Gueorguieva I, Shcherbinin S, Andersen SW, Hauck PM, Engle SE, et al. Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. Alzheimers Dement. 2025;21:e70062.","journal-title":"Alzheimers Dement"},{"key":"972_CR84","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1474-4422(25)00313-8","volume":"24","author":"BDC Boon","year":"2025","unstructured":"Boon BDC, Piura YD, Moloney CM, Chalk JL, Lincoln SJ, Rutledge MH, Rothberg DM, Kouri N, Hinkle KM, Roemer SF, et al. Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer\u2019s disease treated with aducanumab versus untreated: a retrospective case-control study. Lancet Neurol. 2025;24:931\u201344.","journal-title":"Lancet Neurol"},{"key":"972_CR85","doi-asserted-by":"publisher","first-page":"eads3204","DOI":"10.1126\/science.ads3204","volume":"389","author":"ME Pizzo","year":"2025","unstructured":"Pizzo ME, Plowey ED, Khoury N, Kwan W, Abettan J, DeVos SL, Discenza CB, Earr T, Joy D, Lye-Barthel M, et al. Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA. Science. 2025;389:eads3204.","journal-title":"Science"},{"key":"972_CR86","doi-asserted-by":"publisher","first-page":"640","DOI":"10.4103\/aian.aian_748_25","volume":"28","author":"F Arshad","year":"2025","unstructured":"Arshad F, Alladi S. Disease-Modifying Drugs for Alzheimer\u2019s Disease: Bending the Curve. Ann Indian Acad Neurol. 2025;28:640\u20135.","journal-title":"Ann Indian Acad Neurol"},{"key":"972_CR87","unstructured":"A Study of Remternetug (LY3372993.) in Participants With Alzheimer\u2019s Disease (TRAILRUNNER-ALZ 1). https:\/\/clinicaltrials.gov\/study\/NCT05463731."},{"key":"972_CR88","unstructured":"Early Phase 3. Data Highlight Convenience and Feasibility of Self-Administered Alzheimer Agent Remternetug. https:\/\/www.neurologylive.com\/view\/early-phase-3-data-highlight-convenience-feasibility-self-administered-alzheimer-agent-remternetug."},{"key":"972_CR89","unstructured":"Next Goals for Immunotherapy. Make It Safer, Less of a Hassle. https:\/\/www.alzforum.org\/news\/conference-coverage\/next-goals-immunotherapy-make-it-safer-less-hassle."},{"key":"972_CR90","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvado","year":"2019","unstructured":"Salvado G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suarez-Calvet M, Pavia J, Ninerola-Baizan A, Perissinotti A, Lomena F, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11:27.","journal-title":"Alzheimers Res Ther"},{"key":"972_CR91","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","volume":"38","author":"J Cummings","year":"2024","unstructured":"Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer\u2019s Disease. BioDrugs. 2024;38:5\u201322.","journal-title":"BioDrugs"},{"key":"972_CR92","unstructured":"A Study of Remternetug (LY3372993.) in Early Alzheimer\u2019s Disease (TRAILRUNNER-ALZ 3). https:\/\/clinicaltrials.gov\/study\/NCT06653153."},{"key":"972_CR93","doi-asserted-by":"publisher","first-page":"2261509","DOI":"10.1080\/19420862.2023.2261509","volume":"15","author":"HP Grimm","year":"2023","unstructured":"Grimm HP, Schumacher V, Schafer M, Imhof-Jung S, Freskgard PO, Brady K, Hofmann C, Ruger P, Schlothauer T, Gopfert U, et al. Delivery of the Brainshuttle amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. MAbs. 2023;15:2261509.","journal-title":"MAbs"},{"key":"972_CR94","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","volume":"81","author":"J Niewoehner","year":"2014","unstructured":"Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P, Stracke JO, Lau W, Tissot AC, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81:49\u201360.","journal-title":"Neuron"},{"key":"972_CR95","unstructured":"Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer\u2019s at AD\/PD. 2025. https:\/\/www.drugs.com\/clinical_trials\/genentech-roche-present-novel-therapeutic-diagnostic-advancements-alzheimer-s-ad-pd-2025-21995.html."},{"key":"972_CR96","unstructured":"Luka Kulic FA, Klein G, Hofmann C, Yilmaz S, Abrantes JA, Sickert D, Marchesi M, Wojtowicz J, Croney R, Agnew D. Silke Ahlers, Paul Delmar, Hanno Svobada, Iris Wiesel et al. Trontinemab\u2014from early preclinical groundwork to the clinical validation of the Brainshuttle\u2122 platform. In: Ahlers S, Delmar P, Svobada H, Wiesel I, editors. Trontinemab\u2014from early preclinical groundwork to the clinical validation of the Brainshuttle\u2122 platform. 2025."},{"key":"972_CR97","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12974-015-0379-4","volume":"12","author":"YH Liu","year":"2015","unstructured":"Liu YH, Bu XL, Liang CR, Wang YR, Zhang T, Jiao SS, Zeng F, Yao XQ, Zhou HD, Deng J, Wang YJ. An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect. J Neuroinflammation. 2015;12:153.","journal-title":"J Neuroinflammation"},{"key":"972_CR98","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1073\/pnas.0436286100","volume":"100","author":"F Bard","year":"2003","unstructured":"Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer\u2019s disease-like neuropathology. Proc Natl Acad Sci U S A. 2003;100:2023\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"972_CR99","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/WNR.0b013e3280148e76","volume":"18","author":"AJ Gray","year":"2007","unstructured":"Gray AJ, Sakaguchi G, Shiratori C, Becker AG, LaFrancois J, Aisen PS, Duff K, Matsuoka Y. Antibody against C-terminal Abeta selectively elevates plasma Abeta. NeuroReport. 2007;18:293\u20136.","journal-title":"NeuroReport"},{"key":"972_CR100","doi-asserted-by":"crossref","unstructured":"Liu YH, Wang J, Li QX, Fowler CJ, Zeng F, Deng J, Xu ZQ, Zhou HD, Doecke JD, Villemagne VL, et al. Association of naturally occurring antibodies to \u03b2-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer\u2019s disease. Sci Adv. 2021;7(3):eabb0457.","DOI":"10.1126\/sciadv.abb0457"},{"key":"972_CR101","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0002-9440(10)64700-1","volume":"156","author":"GK Gouras","year":"2000","unstructured":"Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156:15\u201320.","journal-title":"Am J Pathol"},{"key":"972_CR102","doi-asserted-by":"publisher","first-page":"9513","DOI":"10.1073\/pnas.90.20.9513","volume":"90","author":"AM Wertkin","year":"1993","unstructured":"Wertkin AM, Turner RS, Pleasure SJ, Golde TE, Younkin SG, Trojanowski JQ, Lee VM. Human neurons derived from a teratocarcinoma cell line express solely the 695-amino acid amyloid precursor protein and produce intracellular beta-amyloid or A4 peptides. Proc Natl Acad Sci U S A. 1993;90:9513\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"972_CR103","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nm0196-93","volume":"2","author":"JK Teller","year":"1996","unstructured":"Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, Scartezzini P, Bertolini S, Mann DM, Tabaton M, Gambetti P. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down\u2019s syndrome. Nat Med. 1996;2:93\u20135.","journal-title":"Nat Med"},{"key":"972_CR104","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","volume":"46","author":"CA McLean","year":"1999","unstructured":"McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer\u2019s disease. Ann Neurol. 1999;46:860\u20136.","journal-title":"Ann Neurol"},{"key":"972_CR105","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409\u201321.","journal-title":"Neuron"},{"key":"972_CR106","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129\u201340.","journal-title":"J Neurosci"},{"key":"972_CR107","doi-asserted-by":"crossref","unstructured":"Kobro-Flatmoen A, Nagelhus A, Witter MP. Reelin-immunoreactive neurons in entorhinal cortex layer II selectively express intracellular amyloid in early Alzheimer\u2019s disease. Neurobiol Dis. 2016;93:172\u201383.","DOI":"10.1016\/j.nbd.2016.05.012"},{"key":"972_CR108","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1073\/pnas.1914593117","volume":"117","author":"LA Welikovitch","year":"2020","unstructured":"Welikovitch LA, Do Carmo S, Magloczky Z, Malcolm JC, Loke J, Klein WL, Freund T, Cuello AC. Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. Proc Natl Acad Sci U S A. 2020;117:6844\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"972_CR109","doi-asserted-by":"crossref","unstructured":"Tampellini D, Gouras GK. Synapses, synaptic activity and intraneuronal A\u03b2 in Alzheimer\u2019s disease. Front Aging Neurosci. 2010;2:13.","DOI":"10.3389\/fnagi.2010.00013"},{"key":"972_CR110","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.1038\/s41467-025-60328-w","volume":"16","author":"A Caramello","year":"2025","unstructured":"Caramello A, Fancy N, Tournerie C, Eklund M, Chau V, Adair E, Papageorgopoulou M, Willumsen N, Jackson JS, Hardy J, Matthews PM. Intracellular accumulation of amyloid-ss is a marker of selective neuronal vulnerability in Alzheimer\u2019s disease. Nat Commun. 2025;16:5189.","journal-title":"Nat Commun"},{"key":"972_CR111","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.neuron.2020.06.010","volume":"107","author":"JP Roussarie","year":"2020","unstructured":"Roussarie JP, Yao V, Rodriguez-Rodriguez P, Oughtred R, Rust J, Plautz Z, Kasturia S, Albornoz C, Wang W, Schmidt EF, et al. Selective Neuronal Vulnerability in Alzheimer\u2019s Disease: A Network-Based Analysis. Neuron. 2020;107:821\u2013e835812.","journal-title":"Neuron"},{"key":"972_CR112","doi-asserted-by":"publisher","first-page":"9704","DOI":"10.1523\/JNEUROSCI.2292-09.2009","volume":"29","author":"D Tampellini","year":"2009","unstructured":"Tampellini D, Rahman N, Gallo EF, Huang Z, Dumont M, Capetillo-Zarate E, Ma T, Zheng R, Lu B, Nanus DM, et al. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci. 2009;29:9704\u201313.","journal-title":"J Neurosci"},{"key":"972_CR113","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nn.2801","volume":"14","author":"AW Bero","year":"2011","unstructured":"Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci. 2011;14:750\u20136.","journal-title":"Nat Neurosci"},{"key":"972_CR114","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.neuron.2005.01.040","volume":"45","author":"LM Billings","year":"2005","unstructured":"Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer\u2019s disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675\u201388.","journal-title":"Neuron"},{"key":"972_CR115","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.neurobiolaging.2006.06.019","volume":"28","author":"M Knobloch","year":"2007","unstructured":"Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging. 2007;28:1297\u2013306.","journal-title":"Neurobiol Aging"},{"key":"972_CR116","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/2051-5960-2-61","volume":"2","author":"MF Iulita","year":"2014","unstructured":"Iulita MF, Allard S, Richter L, Munter LM, Ducatenzeiler A, Weise C, Do Carmo S, Klein WL, Multhaup G, Cuello AC. Intracellular Abeta pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathol Commun. 2014;2:61.","journal-title":"Acta Neuropathol Commun"},{"key":"972_CR117","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nn842","volume":"5","author":"JC Dodart","year":"2002","unstructured":"Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer\u2019s disease model. Nat Neurosci. 2002;5:452\u20137.","journal-title":"Nat Neurosci"},{"key":"972_CR118","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2353\/ajpath.2006.050593","volume":"168","author":"S Oddo","year":"2006","unstructured":"Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol. 2006;168:184\u201394.","journal-title":"Am J Pathol"},{"key":"972_CR119","doi-asserted-by":"publisher","first-page":"18895","DOI":"10.1074\/jbc.M700373200","volume":"282","author":"D Tampellini","year":"2007","unstructured":"Tampellini D, Magrane J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem. 2007;282:18895\u2013906.","journal-title":"J Biol Chem"},{"key":"972_CR120","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.neuron.2004.07.003","volume":"43","author":"S Oddo","year":"2004","unstructured":"Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321\u201332.","journal-title":"Neuron"},{"key":"972_CR121","doi-asserted-by":"publisher","first-page":"35452","DOI":"10.1074\/jbc.M113.491001","volume":"288","author":"EE Congdon","year":"2013","unstructured":"Congdon EE, Gu J, Sait HB, Sigurdsson EM. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem. 2013;288:35452\u201365.","journal-title":"J Biol Chem"},{"key":"972_CR122","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1093\/brain\/awu213","volume":"137","author":"L Collin","year":"2014","unstructured":"Collin L, Bohrmann B, Gopfert U, Oroszlan-Szovik K, Ozmen L, Gruninger F. Neuronal uptake of tau\/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer\u2019s disease. Brain. 2014;137:2834\u201346.","journal-title":"Brain"},{"key":"972_CR123","doi-asserted-by":"publisher","first-page":"eadj5958","DOI":"10.1126\/scitranslmed.adj5958","volume":"16","author":"S Gaikwad","year":"2024","unstructured":"Gaikwad S, Puangmalai N, Sonawane M, Montalbano M, Price R, Iyer MS, Ray A, Moreno S, Kayed R. Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice. Sci Transl Med. 2024;16:eadj5958.","journal-title":"Sci Transl Med"},{"key":"972_CR124","doi-asserted-by":"publisher","first-page":"588021","DOI":"10.3389\/fimmu.2020.588021","volume":"11","author":"S Zia","year":"2020","unstructured":"Zia S, Rawji KS, Michaels NJ, Burr M, Kerr BJ, Healy LM, Plemel JR. Microglia Diversity in Health and Multiple Sclerosis. Front Immunol. 2020;11:588021.","journal-title":"Front Immunol"},{"key":"972_CR125","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","volume":"35","author":"M Colonna","year":"2017","unstructured":"Colonna M, Butovsky O. Microglia Function in the Central Nervous System During Health and Neurodegeneration. Annu Rev Immunol. 2017;35:441\u201368.","journal-title":"Annu Rev Immunol"},{"key":"972_CR126","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1038\/s41467-021-23111-1","volume":"12","author":"A Grubman","year":"2021","unstructured":"Grubman A, Choo XY, Chew G, Ouyang JF, Sun G, Croft NP, Rossello FJ, Simmons R, Buckberry S, Landin DV, et al. Transcriptional signature in microglia associated with Abeta plaque phagocytosis. Nat Commun. 2021;12:3015.","journal-title":"Nat Commun"},{"key":"972_CR127","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1172\/JCI77487","volume":"125","author":"JU Johansson","year":"2015","unstructured":"Johansson JU, Woodling NS, Wang Q, Panchal M, Liang X, Trueba-Saiz A, Brown HD, Mhatre SD, Loui T, Andreasson KI. Prostaglandin signaling suppresses beneficial microglial function in Alzheimer\u2019s disease models. J Clin Invest. 2015;125:350\u201364.","journal-title":"J Clin Invest"},{"key":"972_CR128","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13024-017-0188-6","volume":"12","author":"R Zhao","year":"2017","unstructured":"Zhao R, Hu W, Tsai J, Li W, Gan WB. Microglia limit the expansion of beta-amyloid plaques in a mouse model of Alzheimer\u2019s disease. Mol Neurodegener. 2017;12:47.","journal-title":"Mol Neurodegener"},{"key":"972_CR129","doi-asserted-by":"publisher","first-page":"8354","DOI":"10.1523\/JNEUROSCI.0616-08.2008","volume":"28","author":"SE Hickman","year":"2008","unstructured":"Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer\u2019s disease mice. J Neurosci. 2008;28:8354\u201360.","journal-title":"J Neurosci"},{"key":"972_CR130","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jneuroim.2009.02.003","volume":"210","author":"A Michelucci","year":"2009","unstructured":"Michelucci A, Heurtaux T, Grandbarbe L, Morga E, Heuschling P. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol. 2009;210:3\u201312.","journal-title":"J Neuroimmunol"},{"key":"972_CR131","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41593-021-00951-0","volume":"25","author":"P d\u2019Errico","year":"2022","unstructured":"d\u2019Errico P, Ziegler-Waldkirch S, Aires V, Hoffmann P, Mezo C, Erny D, Monasor LS, Liebscher S, Ravi VM, Joseph K, et al. Microglia contribute to the propagation of Abeta into unaffected brain tissue. Nat Neurosci. 2022;25:20\u20135.","journal-title":"Nat Neurosci"},{"key":"972_CR132","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41467-019-11674-z","volume":"10","author":"E Spangenberg","year":"2019","unstructured":"Spangenberg E, Severson PL, Hohsfield LA, Crapser J, Zhang J, Burton EA, Zhang Y, Spevak W, Lin J, Phan NY, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer\u2019s disease model. Nat Commun. 2019;10:3758.","journal-title":"Nat Commun"},{"key":"972_CR133","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer\u2019s Disease. Cell. 2017;169:1276\u2013e12901217.","journal-title":"Cell"},{"key":"972_CR134","doi-asserted-by":"publisher","first-page":"10634","DOI":"10.1038\/s41467-024-54779-w","volume":"15","author":"N Baligacs","year":"2024","unstructured":"Baligacs N, Albertini G, Borrie SC, Serneels L, Pridans C, Balusu S, De Strooper B. Homeostatic microglia initially seed and activated microglia later reshape amyloid plaques in Alzheimer\u2019s Disease. Nat Commun. 2024;15:10634.","journal-title":"Nat Commun"},{"key":"972_CR135","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O\u2019Loughlin E, Xu Y, Fanek Z, et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity. 2017;47:566\u2013e581569.","journal-title":"Immunity"},{"key":"972_CR136","doi-asserted-by":"publisher","first-page":"578342","DOI":"10.1016\/j.jneuroim.2024.578342","volume":"390","author":"S Fruhwurth","year":"2024","unstructured":"Fruhwurth S, Zetterberg H, Paludan SR. Microglia and amyloid plaque formation in Alzheimer\u2019s disease - Evidence, possible mechanisms, and future challenges. J Neuroimmunol. 2024;390:578342.","journal-title":"J Neuroimmunol"},{"key":"972_CR137","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1523\/JNEUROSCI.23-09-03745.2003","volume":"23","author":"DM Wilcock","year":"2003","unstructured":"Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003;23:3745\u201351.","journal-title":"J Neurosci"},{"key":"972_CR138","doi-asserted-by":"crossref","unstructured":"Albertini G, Zielonka M, Cuypers ML, Snellinx A, Xu C, Poovathingal S, et al. The Alzheimer\u2019s therapeutic Lecanemab attenuates A\u03b2 pathology by inducing an amyloid-clearing program in microglia. Nat Neurosci. 2026;29:100\u201310.","DOI":"10.1038\/s41593-025-02125-8"},{"key":"972_CR139","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41392-022-01273-8","volume":"8","author":"XY Sun","year":"2023","unstructured":"Sun XY, Yu XL, Zhu J, Li LJ, Zhang L, Huang YR, Liu DQ, Ji M, Sun X, Zhang LX, et al. Fc effector of anti-Abeta antibody induces synapse loss and cognitive deficits in Alzheimer\u2019s disease-like mouse model. Signal Transduct Target Ther. 2023;8:30.","journal-title":"Signal Transduct Target Ther"},{"key":"972_CR140","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fnins.2018.00254","volume":"12","author":"IL Sumner","year":"2018","unstructured":"Sumner IL, Edwards RA, Asuni AA, Teeling JL. Antibody Engineering for Optimized Immunotherapy in Alzheimer\u2019s Disease. Front Neurosci. 2018;12:254.","journal-title":"Front Neurosci"},{"key":"972_CR141","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34\u201347.","journal-title":"Nat Rev Immunol"},{"key":"972_CR142","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","volume":"343","author":"CA Diebolder","year":"2014","unstructured":"Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343:1260\u20133.","journal-title":"Science"},{"key":"972_CR143","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1084\/jem.188.3.431","volume":"188","author":"BM Bradt","year":"1998","unstructured":"Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer\u2019s disease beta-peptide. J Exp Med. 1998;188:431\u20138.","journal-title":"J Exp Med"},{"key":"972_CR144","doi-asserted-by":"publisher","first-page":"7496","DOI":"10.4049\/jimmunol.166.12.7496","volume":"166","author":"SD Webster","year":"2001","unstructured":"Webster SD, Galvan MD, Ferran E, Garzon-Rodriguez W, Glabe CG, Tenner AJ. Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. J Immunol. 2001;166:7496\u2013503.","journal-title":"J Immunol"},{"issue":"Suppl 1","key":"972_CR145","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1471-4159.2011.07510.x","volume":"120","author":"NN Nalivaeva","year":"2012","unstructured":"Nalivaeva NN, Beckett C, Belyaev ND, Turner AJ. Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer\u2019s disease? J Neurochem. 2012;120(Suppl 1):167\u201385.","journal-title":"J Neurochem"},{"key":"972_CR146","doi-asserted-by":"publisher","first-page":"10939","DOI":"10.1523\/JNEUROSCI.2085-06.2006","volume":"26","author":"KJ Yin","year":"2006","unstructured":"Yin KJ, Cirrito JR, Yan P, Hu X, Xiao Q, Pan X, Bateman R, Song H, Hsu FF, Turk J, et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci. 2006;26:10939\u201348.","journal-title":"J Neurosci"},{"key":"972_CR147","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41573-022-00390-x","volume":"21","author":"HG Lee","year":"2022","unstructured":"Lee HG, Wheeler MA, Quintana FJ. Function and therapeutic value of astrocytes in neurological diseases. Nat Rev Drug Discov. 2022;21:339\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"972_CR148","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/glia.21004","volume":"58","author":"HM Nielsen","year":"2010","unstructured":"Nielsen HM, Mulder SD, Belien JA, Musters RJ, Eikelenboom P, Veerhuis R. Astrocytic A beta 1\u201342 uptake is determined by A beta-aggregation state and the presence of amyloid-associated proteins. Glia. 2010;58:1235\u201346.","journal-title":"Glia"},{"key":"972_CR149","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1096\/fj.12-208660","volume":"27","author":"AW Kraft","year":"2013","unstructured":"Kraft AW, Hu X, Yoon H, Yan P, Xiao Q, Wang Y, Gil SC, Brown J, Wilhelmsson U, Restivo JL, et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP\/PS1 mice. FASEB J. 2013;27:187\u201398.","journal-title":"FASEB J"},{"key":"972_CR150","doi-asserted-by":"publisher","first-page":"13959","DOI":"10.1074\/jbc.M111.288746","volume":"287","author":"JM Basak","year":"2012","unstructured":"Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM. Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Abeta uptake and degradation by astrocytes. J Biol Chem. 2012;287:13959\u201371.","journal-title":"J Biol Chem"},{"key":"972_CR151","doi-asserted-by":"publisher","first-page":"9607","DOI":"10.1523\/JNEUROSCI.3788-13.2014","volume":"34","author":"Q Xiao","year":"2014","unstructured":"Xiao Q, Yan P, Ma X, Liu H, Perez R, Zhu A, Gonzales E, Burchett JM, Schuler DR, Cirrito JR, et al. Enhancing astrocytic lysosome biogenesis facilitates Abeta clearance and attenuates amyloid plaque pathogenesis. J Neurosci. 2014;34:9607\u201320.","journal-title":"J Neurosci"},{"key":"972_CR152","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0006-8993(03)02361-8","volume":"971","author":"RG Nagele","year":"2003","unstructured":"Nagele RG, D\u2019Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 2003;971:197\u2013209.","journal-title":"Brain Res"},{"key":"972_CR153","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1523\/JNEUROSCI.3442-16.2017","volume":"37","author":"CC Liu","year":"2017","unstructured":"Liu CC, Hu J, Zhao N, Wang J, Wang N, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G. Astrocytic LRP1 Mediates Brain Abeta Clearance and Impacts Amyloid Deposition. J Neurosci. 2017;37:4023\u201331.","journal-title":"J Neurosci"},{"key":"972_CR154","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13024-016-0098-z","volume":"11","author":"S Sollvander","year":"2016","unstructured":"Sollvander S, Nikitidou E, Brolin R, Soderberg L, Sehlin D, Lannfelt L, Erlandsson A. Accumulation of amyloid-beta by astrocytes result in enlarged endosomes and microvesicle-induced apoptosis of neurons. Mol Neurodegener. 2016;11:38.","journal-title":"Mol Neurodegener"},{"key":"972_CR155","doi-asserted-by":"publisher","first-page":"eads3972","DOI":"10.1126\/science.ads3972","volume":"391","author":"Y Chen","year":"2026","unstructured":"Chen Y, Liu Y, Nguyen K, Wu J, Song S, Lin K, Rodrigues PF, Du S, Zhou C, Xiong K, et al. Targeting amyloid-beta pathology by chimeric antigen receptor astrocyte (CAR-A) therapy. Science. 2026;391:eads3972.","journal-title":"Science"},{"key":"972_CR156","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrn2797","volume":"11","author":"KA Nave","year":"2010","unstructured":"Nave KA. Myelination and the trophic support of long axons. Nat Rev Neurosci. 2010;11:275\u201383.","journal-title":"Nat Rev Neurosci"},{"key":"972_CR157","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/nan.12618","volume":"46","author":"I Ferrer","year":"2020","unstructured":"Ferrer I, Andres-Benito P. White matter alterations in Alzheimer\u2019s disease without concomitant pathologies. Neuropathol Appl Neurobiol. 2020;46:654\u201372.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"972_CR158","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.neurobiolaging.2020.05.016","volume":"94","author":"I Vanzulli","year":"2020","unstructured":"Vanzulli I, Papanikolaou M, De-La-Rocha IC, Pieropan F, Rivera AD, Gomez-Nicola D, Verkhratsky A, Rodriguez JJ, Butt AM. Disruption of oligodendrocyte progenitor cells is an early sign of pathology in the triple transgenic mouse model of Alzheimer\u2019s disease. Neurobiol Aging. 2020;94:130\u20139.","journal-title":"Neurobiol Aging"},{"key":"972_CR159","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40035-023-00385-7","volume":"12","author":"P Zou","year":"2023","unstructured":"Zou P, Wu C, Liu TC, Duan R, Yang L. Oligodendrocyte progenitor cells in Alzheimer\u2019s disease: from physiology to pathology. Transl Neurodegener. 2023;12:52.","journal-title":"Transl Neurodegener"},{"key":"972_CR160","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-018-0515-3","volume":"6","author":"SE Nasrabady","year":"2018","unstructured":"Nasrabady SE, Rizvi B, Goldman JE, Brickman AM. White matter changes in Alzheimer\u2019s disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun. 2018;6:22.","journal-title":"Acta Neuropathol Commun"},{"key":"972_CR161","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.neuron.2021.05.012","volume":"109","author":"JF Chen","year":"2021","unstructured":"Chen JF, Liu K, Hu B, Li RR, Xin W, Chen H, Wang F, Chen L, Li RX, Ren SY, et al. Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer\u2019s disease. Neuron. 2021;109:2292\u2013e23072295.","journal-title":"Neuron"},{"key":"972_CR162","doi-asserted-by":"publisher","first-page":"e3002727","DOI":"10.1371\/journal.pbio.3002727","volume":"22","author":"RM Rajani","year":"2024","unstructured":"Rajani RM, Ellingford R, Hellmuth M, Harris SS, Taso OS, Graykowski D, Lam FKW, Arber C, Fertan E, Danial JSH, et al. Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer\u2019s disease. PLoS Biol. 2024;22:e3002727.","journal-title":"PLoS Biol"},{"key":"972_CR163","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/s41593-024-01730-3","volume":"27","author":"AO Sasmita","year":"2024","unstructured":"Sasmita AO, Depp C, Nazarenko T, Sun T, Siems SB, Ong EC, Nkeh YB, Bohler C, Yu X, Bues B, et al. Oligodendrocytes produce amyloid-beta and contribute to plaque formation alongside neurons in Alzheimer\u2019s disease model mice. Nat Neurosci. 2024;27:1668\u201374.","journal-title":"Nat Neurosci"},{"key":"972_CR164","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41593-019-0372-9","volume":"22","author":"P Zhang","year":"2019","unstructured":"Zhang P, Kishimoto Y, Grammatikakis I, Gottimukkala K, Cutler RG, Zhang S, Abdelmohsen K, Bohr VA, Misra Sen J, Gorospe M, Mattson MP. Senolytic therapy alleviates Abeta-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer\u2019s disease model. Nat Neurosci. 2019;22:719\u201328.","journal-title":"Nat Neurosci"},{"key":"972_CR165","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/brain\/awad304","volume":"147","author":"W Wen","year":"2024","unstructured":"Wen W, Cheng J, Tang Y. Brain perivascular macrophages: current understanding and future prospects. Brain. 2024;147:39\u201355.","journal-title":"Brain"},{"key":"972_CR166","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/cns.13263","volume":"25","author":"T Yang","year":"2019","unstructured":"Yang T, Guo R, Zhang F. Brain perivascular macrophages: Recent advances and implications in health and diseases. CNS Neurosci Ther. 2019;25:1318\u201328.","journal-title":"CNS Neurosci Ther"},{"key":"972_CR167","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1111\/cns.13954","volume":"28","author":"L Zheng","year":"2022","unstructured":"Zheng L, Guo Y, Zhai X, Zhang Y, Chen W, Zhu Z, Xuan W, Li P. Perivascular macrophages in the CNS: From health to neurovascular diseases. CNS Neurosci Ther. 2022;28:1908\u201320.","journal-title":"CNS Neurosci Ther"},{"key":"972_CR168","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00401-023-02676-9","volume":"147","author":"A Dalmau Gasull","year":"2024","unstructured":"Dalmau Gasull A, Glavan M, Samawar SKR, Kapupara K, Kelk J, Rubio M, Fumagalli S, Sorokin L, Vivien D, Prinz M. The niche matters: origin, function and fate of CNS-associated macrophages during health and disease. Acta Neuropathol. 2024;147:37.","journal-title":"Acta Neuropathol"},{"key":"972_CR169","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12974-024-03059-x","volume":"21","author":"R Sun","year":"2024","unstructured":"Sun R, Jiang H. Border-associated macrophages in the central nervous system. J Neuroinflammation. 2024;21:67.","journal-title":"J Neuroinflammation"},{"key":"972_CR170","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00109-017-1573-x","volume":"95","author":"G Faraco","year":"2017","unstructured":"Faraco G, Park L, Anrather J, Iadecola C. Brain perivascular macrophages: characterization and functional roles in health and disease. J Mol Med (Berl). 2017;95:1143\u201352.","journal-title":"J Mol Med (Berl)"},{"key":"972_CR171","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41419-025-07592-2","volume":"16","author":"X Zhan","year":"2025","unstructured":"Zhan X, Wang S, Bechet N, Gouras G, Wen G. Perivascular macrophages in the central nervous system: insights into their roles in health and disease. Cell Death Dis. 2025;16:350.","journal-title":"Cell Death Dis"},{"key":"972_CR172","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40364-024-00624-7","volume":"12","author":"H Ma","year":"2024","unstructured":"Ma H, Zhu M, Chen M, Li X, Feng X. The role of macrophage plasticity in neurodegenerative diseases. Biomark Res. 2024;12:81.","journal-title":"Biomark Res"},{"key":"972_CR173","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41586-022-05397-3","volume":"611","author":"A Drieu","year":"2022","unstructured":"Drieu A, Du S, Storck SE, Rustenhoven J, Papadopoulos Z, Dykstra T, Zhong F, Kim K, Blackburn S, Mamuladze T, et al. Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid. Nature. 2022;611:585\u201393.","journal-title":"Nature"},{"key":"972_CR174","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1073\/pnas.0805453106","volume":"106","author":"CA Hawkes","year":"2009","unstructured":"Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci U S A. 2009;106:1261\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"972_CR175","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10571-025-01590-w","volume":"45","author":"M Zhang","year":"2025","unstructured":"Zhang M, Liu S, Zhao Y, Wu P, Tian S, Wu Z, Li S. Molecular Mechanisms of Perivascular Macrophages in Alzheimer\u2019s Disease: Insights from Single-Cell Sequencing and Mendelian Randomization. Cell Mol Neurobiol. 2025;45:65.","journal-title":"Cell Mol Neurobiol"},{"key":"972_CR176","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamaneurol.2024.2579","volume":"81","author":"L Liu","year":"2024","unstructured":"Liu L, Saba A, Pascual JR, Miller MB, Hennessey EL, Lott IT, Brickman AM, Wilcock DM, Harp JP, Schmitt FA, et al. Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down Syndrome. JAMA Neurol. 2024;81:1066\u201372.","journal-title":"JAMA Neurol"},{"key":"972_CR177","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3389\/fimmu.2019.01534","volume":"10","author":"Y Chantran","year":"2019","unstructured":"Chantran Y, Capron J, Alamowitch S, Aucouturier P. Anti-Abeta Antibodies and Cerebral Amyloid Angiopathy Complications. Front Immunol. 2019;10:1534.","journal-title":"Front Immunol"},{"key":"972_CR178","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Marsica Grassi C, Castrillo-Viguera C, Rubino I, Vijverberg E. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer\u2019s Disease Treated with Anti-Amyloid Beta Therapy. J Prev Alzheimers Dis. 2022;9:211\u201320.","journal-title":"J Prev Alzheimers Dis"},{"key":"972_CR179","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146:4414\u201324.","journal-title":"Brain"},{"key":"972_CR180","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ana.26511","volume":"92","author":"N Joseph-Mathurin","year":"2022","unstructured":"Joseph-Mathurin N, Llibre-Guerra JJ, Li Y, McCullough AA, Hofmann C, Wojtowicz J, Park E, Wang G, Preboske GM, Wang Q, et al. Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. Ann Neurol. 2022;92:729\u201344.","journal-title":"Ann Neurol"},{"key":"972_CR181","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, Suhy J, Forrestal F, Tian Y, Umans K, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol. 2022;79:13\u201321.","journal-title":"JAMA Neurol"},{"key":"972_CR182","doi-asserted-by":"crossref","unstructured":"Schreiner TG, Croitoru CG, Hodorog DN, Cuciureanu DI. Passive anti-amyloid beta immunotherapies in Alzheimer\u2019s disease: from mechanisms to therapeutic impact. Biomedicines. 2024;12(5):1096.","DOI":"10.3390\/biomedicines12051096"},{"key":"972_CR183","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1742-2094-8-115","volume":"8","author":"DM Wilcock","year":"2011","unstructured":"Wilcock DM, Morgan D, Gordon MN, Taylor TL, Ridnour LA, Wink DA, Colton CA. Activation of matrix metalloproteinases following anti-Abeta immunotherapy; implications for microhemorrhage occurrence. J Neuroinflammation. 2011;8:115.","journal-title":"J Neuroinflammation"},{"key":"972_CR184","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/brain\/awn261","volume":"131","author":"D Boche","year":"2008","unstructured":"Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA. Consequence of Abeta immunization on the vasculature of human Alzheimer\u2019s disease brain. Brain. 2008;131:3299\u2013310.","journal-title":"Brain"},{"key":"972_CR185","doi-asserted-by":"crossref","unstructured":"Mummery CJ, Mayorga AJ, Simmons A, Chow TW, Burgess B, Nguyen T, Gao J, Budda B, Park LQ, Gupta R, et al. The TREM2 agonistic antibody AL002 in early Alzheimer\u2019s disease: a phase 2 randomized trial. Nat Med. 2026;32(5):1708\u201316.","DOI":"10.1038\/s41591-026-04273-1"},{"key":"972_CR186","doi-asserted-by":"publisher","first-page":"S355","DOI":"10.3233\/JAD-221016","volume":"94","author":"X Guo","year":"2023","unstructured":"Guo X, Zhang G, Peng Q, Huang L, Zhang Z, Zhang Z. Emerging Roles of Meningeal Lymphatic Vessels in Alzheimer\u2019s Disease. J Alzheimers Dis. 2023;94:S355\u201366.","journal-title":"J Alzheimers Dis"},{"key":"972_CR187","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13024-019-0312-x","volume":"14","author":"TK Patel","year":"2019","unstructured":"Patel TK, Habimana-Griffin L, Gao X, Xu B, Achilefu S, Alitalo K, McKee CA, Sheehan PW, Musiek ES, Xiong C, et al. Dural lymphatics regulate clearance of extracellular tau from the CNS. Mol Neurodegener. 2019;14:11.","journal-title":"Mol Neurodegener"},{"key":"972_CR188","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s42003-024-05911-5","volume":"7","author":"E Licastro","year":"2024","unstructured":"Licastro E, Pignataro G, Iliff JJ, Xiang Y, Lo EH, Hayakawa K, Esposito E. Glymphatic and lymphatic communication with systemic responses during physiological and pathological conditions in the central nervous system. Commun Biol. 2024;7:229.","journal-title":"Commun Biol"},{"key":"972_CR189","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13024-023-00618-3","volume":"18","author":"DA Formolo","year":"2023","unstructured":"Formolo DA, Yu J, Lin K, Tsang HWH, Ou H, Kranz GS, Yau SY. Leveraging the glymphatic and meningeal lymphatic systems as therapeutic strategies in Alzheimer\u2019s disease: an updated overview of nonpharmacological therapies. Mol Neurodegener. 2023;18:26.","journal-title":"Mol Neurodegener"},{"key":"972_CR190","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1172\/JCI90603","volume":"127","author":"A Louveau","year":"2017","unstructured":"Louveau A, Plog BA, Antila S, Alitalo K, Nedergaard M, Kipnis J. Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. J Clin Invest. 2017;127:3210\u20139.","journal-title":"J Clin Invest"},{"key":"972_CR191","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41586-018-0368-8","volume":"560","author":"S Da Mesquita","year":"2018","unstructured":"Da Mesquita S, Louveau A, Vaccari A, Smirnov I, Cornelison RC, Kingsmore KM, Contarino C, Onengut-Gumuscu S, Farber E, Raper D, et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer\u2019s disease. Nature. 2018;560:185\u201391.","journal-title":"Nature"},{"key":"972_CR192","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bpa.12656","volume":"29","author":"L Wang","year":"2019","unstructured":"Wang L, Zhang Y, Zhao Y, Marshall C, Wu T, Xiao M. Deep cervical lymph node ligation aggravates AD-like pathology of APP\/PS1 mice. Brain Pathol. 2019;29:176\u201392.","journal-title":"Brain Pathol"},{"key":"972_CR193","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/s41467-024-45656-7","volume":"15","author":"M Wang","year":"2024","unstructured":"Wang M, Yan C, Li X, Yang T, Wu S, Liu Q, Luo Q, Zhou F. Non-invasive modulation of meningeal lymphatics ameliorates ageing and Alzheimer\u2019s disease-associated pathology and cognition in mice. Nat Commun. 2024;15:1453.","journal-title":"Nat Commun"},{"key":"972_CR194","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3233\/JAD-181177","volume":"68","author":"H Guo","year":"2019","unstructured":"Guo H, Zhao Z, Zhang R, Chen P, Zhang X, Cheng F, Gou X. Monocytes in the Peripheral Clearance of Amyloid-beta and Alzheimer\u2019s Disease. J Alzheimers Dis. 2019;68:1391\u2013400.","journal-title":"J Alzheimers Dis"},{"key":"972_CR195","doi-asserted-by":"crossref","unstructured":"Tian C, Ao Z, Cerneckis J, Cai H, Chen L, Niu H, Takayama K, Kim J, Shi Y, Gu M, Kanekiyo T, Guo F. Understanding monocyte-driven neuroinflammation in Alzheimer\u2019s disease using human cortical organoid microphysiological systems. Sci Adv. 2025;11:eadu2708.","DOI":"10.1126\/sciadv.adu2708"},{"key":"972_CR196","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00401-015-1477-1","volume":"130","author":"Y Xiang","year":"2015","unstructured":"Xiang Y, Bu XL, Liu YH, Zhu C, Shen LL, Jiao SS, Zhu XY, Giunta B, Tan J, Song WH, et al. Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer\u2019s disease. Acta Neuropathol. 2015;130:487\u201399.","journal-title":"Acta Neuropathol"},{"key":"972_CR197","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1084\/jem.20151428","volume":"213","author":"CM Yuede","year":"2016","unstructured":"Yuede CM, Lee H, Restivo JL, Davis TA, Hettinger JC, Wallace CE, Young KL, Hayne MR, Bu G, Li CZ, Cirrito JR. Rapid in vivo measurement of beta-amyloid reveals biphasic clearance kinetics in an Alzheimer\u2019s mouse model. J Exp Med. 2016;213:677\u201385.","journal-title":"J Exp Med"},{"key":"972_CR198","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.celrep.2013.10.010","volume":"5","author":"JP Michaud","year":"2013","unstructured":"Michaud JP, Bellavance MA, Prefontaine P, Rivest S. Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta. Cell Rep. 2013;5:646\u201353.","journal-title":"Cell Rep"},{"key":"972_CR199","doi-asserted-by":"crossref","unstructured":"Yan P, Kim KW, Xiao Q, Ma X, Czerniewski LR, Liu H, Rawnsley DR, Yan Y, Randolph GJ, Epelman S, et al. Peripheral monocyte-derived cells counter amyloid plaque pathogenesis in a mouse model of Alzheimer\u2019s disease. J Clin Invest. 2022;132(11):e152565.","DOI":"10.1172\/JCI152565"},{"key":"972_CR200","doi-asserted-by":"publisher","first-page":"7998","DOI":"10.1038\/s41467-024-52396-1","volume":"15","author":"X Huang","year":"2024","unstructured":"Huang X, Fowler C, Li Y, Li QX, Sun J, Pan Y, Jin L, Perez KA, Dubois C, Lim YY, et al. Clearance and transport of amyloid beta by peripheral monocytes correlate with Alzheimer\u2019s disease progression. Nat Commun. 2024;15:7998.","journal-title":"Nat Commun"},{"key":"972_CR201","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41467-024-45627-y","volume":"15","author":"K Juul-Madsen","year":"2024","unstructured":"Juul-Madsen K, Parbo P, Ismail R, Ovesen PL, Schmidt V, Madsen LS, Thyrsted J, Gierl S, Breum M, Larsen A, et al. Amyloid-beta aggregates activate peripheral monocytes in mild cognitive impairment. Nat Commun. 2024;15:1224.","journal-title":"Nat Commun"},{"key":"972_CR202","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00401-016-1596-3","volume":"132","author":"BJ Gu","year":"2016","unstructured":"Gu BJ, Huang X, Ou A, Rembach A, Fowler C, Avula PK, Horton A, Doecke JD, Villemagne VL, Macaulay SL, et al. Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer\u2019s disease. Acta Neuropathol. 2016;132:377\u201389.","journal-title":"Acta Neuropathol"},{"key":"972_CR203","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00702-010-0433-4","volume":"117","author":"CY Lee","year":"2010","unstructured":"Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna). 2010;117:949\u201360.","journal-title":"J Neural Transm (Vienna)"},{"key":"972_CR204","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/187152709787601821","volume":"8","author":"D Morgan","year":"2009","unstructured":"Morgan D. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS Neurol Disord Drug Targets. 2009;8:7\u201315.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"972_CR205","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.neuron.2006.01.022","volume":"49","author":"AR Simard","year":"2006","unstructured":"Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer\u2019s disease. Neuron. 2006;49:489\u2013502.","journal-title":"Neuron"},{"key":"972_CR206","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/nm1555","volume":"13","author":"J El Khoury","year":"2007","unstructured":"El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13:432\u20138.","journal-title":"Nat Med"},{"key":"972_CR207","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/nn2015","volume":"10","author":"A Mildner","year":"2007","unstructured":"Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, Bruck W, Priller J, Prinz M. Microglia in the adult brain arise from Ly-6ChiCCR2\u2009+\u2009monocytes only under defined host conditions. Nat Neurosci. 2007;10:1544\u201353.","journal-title":"Nat Neurosci"},{"key":"972_CR208","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1126\/science.1178331","volume":"327","author":"F Geissmann","year":"2010","unstructured":"Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science. 2010;327:656\u201361.","journal-title":"Science"},{"key":"972_CR209","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1126\/science.1142883","volume":"317","author":"C Auffray","year":"2007","unstructured":"Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S, Sarnacki S, Cumano A, Lauvau G, Geissmann F. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007;317:666\u201370.","journal-title":"Science"},{"key":"972_CR210","doi-asserted-by":"publisher","first-page":"203","DOI":"10.25100\/cm.v47i4.2640","volume":"47","author":"A Barrera-Ocampo","year":"2016","unstructured":"Barrera-Ocampo A, Lopera F. Amyloid-beta immunotherapy: the hope for Alzheimer disease? Colomb Med (Cali). 2016;47:203\u201312.","journal-title":"Colomb Med (Cali)"},{"key":"972_CR211","unstructured":"Alzheimer\u2019s Tau Platform. Master Protocol (ATP) [ https:\/\/clinicaltrials.gov\/study\/NCT06957418 ]"},{"key":"972_CR212","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(23)00247-8","volume":"22","author":"K Schlepckow","year":"2023","unstructured":"Schlepckow K, Morenas-Rodriguez E, Hong S, Haass C. Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer\u2019s disease. Lancet Neurol. 2023;22:1048\u201360.","journal-title":"Lancet Neurol"},{"key":"972_CR213","doi-asserted-by":"publisher","first-page":"39374","DOI":"10.1038\/srep39374","volume":"6","author":"M Ultsch","year":"2016","unstructured":"Ultsch M, Li B, Maurer T, Mathieu M, Adolfsson O, Muhs A, Pfeifer A, Pihlgren M, Bainbridge TW, Reichelt M, et al. Structure of Crenezumab Complex with Abeta Shows Loss of beta-Hairpin. Sci Rep. 2016;6:39374.","journal-title":"Sci Rep"},{"key":"972_CR214","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","volume":"79","author":"S Ostrowitzki","year":"2022","unstructured":"Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, Cassetta E, Woodward M, Boada M, van Dyck CH, et al. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. JAMA Neurol. 2022;79:1113\u201321.","journal-title":"JAMA Neurol"},{"key":"972_CR215","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","volume":"90","author":"JL Cummings","year":"2018","unstructured":"Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, et al. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90:e1889\u201397.","journal-title":"Neurology"},{"key":"972_CR216","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-025-00465-w","volume":"14","author":"BH Kim","year":"2025","unstructured":"Kim BH, Kim S, Nam Y, Park YH, Shin SM, Moon M. Second-generation anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: current landscape and future perspectives. Transl Neurodegener. 2025;14:6.","journal-title":"Transl Neurodegener"},{"key":"972_CR217","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-023-00976-6","volume":"30","author":"LK Huang","year":"2023","unstructured":"Huang LK, Kuan YC, Lin HW, Hu CJ. Clinical trials of new drugs for Alzheimer disease: a 2020\u20132023 update. J Biomed Sci. 2023;30:83.","journal-title":"J Biomed Sci"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-026-00972-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-026-00972-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-026-00972-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:03:32Z","timestamp":1784214212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13024-026-00972-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":217,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["972"],"URL":"https:\/\/doi.org\/10.1186\/s13024-026-00972-y","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"37"}}